We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Nonclinical Pharmacokinetics of a New Nonpeptide V2 Receptor Antagonist, Tolvaptan.
- Authors
Furukawa, Masayuki; Umehara, Ken; Kashiyama, Eiji
- Abstract
Purpose: To evaluate the pharmacokinetic profile of tolvaptan. Method: The nonclinical pharmacokinetic profile of [C]tolvaptan was evaluated in an absorption, distribution, and excretion study in rats after single oral administration. An in vitro protein binding study was also performed. Results: The tolvaptan-derived radioactivity was rapidly absorbed and extensively distributed to all tissues in rats. The radioactivity levels were greatest in the gastrointestinal tract and liver, though the levels in the cerebrum, cerebellum and medulla oblongata were low. The serum and tissue concentrations of radioactivity, and serum concentration of tolvaptan in male and female rats showed a marked sex difference. The radioactivity was crossed the placenta and was distributed to the fetal tissues in pregnant rats. The milk showed 1.5-15.8-fold higher radioactivity than blood in lactating rats. The radioactivity mainly excreted into the feces via the biliary route. Tolvaptan binds extensively to plasma proteins (≥97.2%) in mouse, rat, rabbit, dog and human plasma.
- Subjects
PHARMACOKINETICS; RATS; FETAL tissues; TISSUES; BLOOD proteins; SEX differentiation (Embryology); RADIOLIGAND assay
- Publication
Cardiovascular Drugs & Therapy, 2011, Vol 25, p83
- ISSN
0920-3206
- Publication type
Article
- DOI
10.1007/s10557-011-6357-x